JP2012517965A5 - - Google Patents

Download PDF

Info

Publication number
JP2012517965A5
JP2012517965A5 JP2011549472A JP2011549472A JP2012517965A5 JP 2012517965 A5 JP2012517965 A5 JP 2012517965A5 JP 2011549472 A JP2011549472 A JP 2011549472A JP 2011549472 A JP2011549472 A JP 2011549472A JP 2012517965 A5 JP2012517965 A5 JP 2012517965A5
Authority
JP
Japan
Prior art keywords
formula
reaction
above meanings
compound
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011549472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517965A (ja
JP5667085B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/000717 external-priority patent/WO2010091824A1/en
Publication of JP2012517965A publication Critical patent/JP2012517965A/ja
Publication of JP2012517965A5 publication Critical patent/JP2012517965A5/ja
Application granted granted Critical
Publication of JP5667085B2 publication Critical patent/JP5667085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011549472A 2009-02-13 2010-02-05 Aktインヒビターとしての融合されたピリミジン Expired - Fee Related JP5667085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09152805.9 2009-02-13
EP09152805 2009-02-13
PCT/EP2010/000717 WO2010091824A1 (en) 2009-02-13 2010-02-05 Fused pyrimidines as akt inhibitors

Publications (3)

Publication Number Publication Date
JP2012517965A JP2012517965A (ja) 2012-08-09
JP2012517965A5 true JP2012517965A5 (enExample) 2014-09-04
JP5667085B2 JP5667085B2 (ja) 2015-02-12

Family

ID=42019301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549472A Expired - Fee Related JP5667085B2 (ja) 2009-02-13 2010-02-05 Aktインヒビターとしての融合されたピリミジン

Country Status (7)

Country Link
US (1) US20130310362A1 (enExample)
EP (1) EP2396331B1 (enExample)
JP (1) JP5667085B2 (enExample)
CN (1) CN102361872B (enExample)
CA (1) CA2752114C (enExample)
ES (1) ES2435804T3 (enExample)
WO (1) WO2010091824A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505631PA (en) 2013-01-23 2015-08-28 Astrazeneca Ab Chemical compounds
US10526660B2 (en) 2013-09-12 2020-01-07 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP2907811A1 (en) 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
CN110402244B (zh) 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164703A0 (en) * 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2005233584B2 (en) 2004-04-09 2010-12-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2008510823A (ja) 2004-08-23 2008-04-10 メルク エンド カムパニー インコーポレーテッド Akt活性阻害剤
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2008530111A (ja) 2005-02-14 2008-08-07 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
DK1898903T3 (da) 2005-06-10 2013-07-01 Merck Sharp & Dohme Inhibitorer af Akt-aktivitet
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
PA8793301A1 (es) * 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados
PL2188291T3 (pl) * 2007-08-14 2013-06-28 Bayer Ip Gmbh Skondensowane bicykliczne pirymidyny

Similar Documents

Publication Publication Date Title
JP2012517965A5 (enExample)
DK1678119T3 (da) Fremgangsmåde til fremstilling af 2-dihalogenacyl-3-amino-acrylsyreestere og 3-dihalogenmethyl-pyrazol-4-carboxylsyreestere
JP2013010731A5 (ja) 複素環化合物
JP2014516210A5 (enExample)
JP2007518723A5 (enExample)
JP2009523146A5 (enExample)
JP2009539914A5 (enExample)
JP2009539912A5 (enExample)
JP2009120624A5 (enExample)
JP2009135422A5 (enExample)
JP2015524409A5 (enExample)
JP2015042636A5 (ja) 有機化合物
JP2013147496A5 (ja) 有機金属錯体
EA201290401A1 (ru) Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
JP2011121940A5 (ja) 発光素子
JP2013010730A5 (ja) フルオレン化合物および有機化合物
JP2007514047A5 (enExample)
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
JP2013028597A5 (enExample)
CY1108792T1 (el) Παραγωγα διοξανιου-2-αλκυλκαρβαμικου, η παρασκευη τους και η εφαρμογη τους στην θεραπευτικη αγωγη
TW200736363A (en) Material for organic electroluminescent device and organic electroluminescent device
JP2012520247A5 (enExample)
JP2014148663A5 (enExample)
JP2014507383A5 (enExample)
JP2013506729A5 (enExample)